LigaChem Biosciences Inc. (141080KS, hereinafter “LigaChemBio”) and Trican Biotechnology (“Trican”) based in New Taipei City, Taiwan on September 10^th, 2025 jointly announced a research collaboration and exclusive option and license agreement to develop and commercialize a novel ADC therapeutic using antibodies engineered by Trican.

Under the terms of the agreement, LigaChemBio will advance the development and commercialization of ADC products using antibodies generated by Trican. Trican will receive an upfront payment and is eligible to receive progress-dependent regulatory, development, and commercial milestone payments with additional royalties on net product sales.

“We are pleased to enter into a partnership with LigaChemBio with its industry-leading proprietary ADC technology platform,” said Sharon Wang, GM of Trican. “This agreement marks the beginning of a partnership with LigaChemBio to combine the speed and quality from our antibody discovery with ConjuAll technology to create differentiated first and best-in class ADCs with wide therapeutic window to provide potential new treatment options for oncology.”

“We are pleased to enter this agreement with Trican as we continue to expand our toolbox to maximize the value of our ADC platform. We look forward to evaluating and bringing innovative candidates into the clinic,” said Dr. Yong-Zu Kim, CEO of LigaChemBio.